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Background: As meropenem is a restricted antimicrobial, lessons learned from its real-life usage will be applic-
able to antimicrobial stewardship (AMS)more generally.
Objectives: To retrospectively evaluate meropenem usage at our institution to identify targets for AMS
interventions.
Methods: Patients receiving meropenem documented with an ‘alert antimicrobial’ form at two tertiary care UK
hospitals were identified retrospectively. Clinical records andmicrobiology results were reviewed.
Results: A total of 107 adult inpatients receiving meropenem were identified. This was first-line in 47% and es-
calation therapy in 53%. Source control was required in 28% of cases after escalation, for predictable reasons.
Those ultimately requiring source control had received more prior antimicrobial agents than those who did not
(P"0.03). Meropenemwas rationalized in 24% of cases (after median 4 days). Positive microbiology enabled ra-
tionalization (OR 12.3, 95%CI 2.7–55.5, P"0.001) but rates of appropriate sampling varied. In cases with positive
microbiology wheremeropenemwas not rationalized, continuation was retrospectively considered clinically and
microbiologically necessary in 8/40 cases (0/17 empirical first-line usage). Rationalization was more likely when
meropenem susceptibility was not released on themicrobiology report (OR 5.2, 95% CI 1.3–20.2, P"0.02). Input
froman infection specialist was associatedwith a reduced duration ofmeropenem therapy (P,0.0001). Early re-
view by an infection specialist has the potential to further facilitate rationalization.
Conclusions: In real-life clinical practice, core aspects of infection management remain tractable targets for
AMS interventions: microbiological sampling, source control and infection specialist input. Further targets include
supporting rationalization to less familiar carbapenem-sparing antimicrobials, restricting first-line meropenem
usage and selectively reportingmeropenem susceptibility.
Introduction
Careful antimicrobial stewardship (AMS) is essential to decelerate
the emergence of resistance to currently available drugs, and thus
preserve their efficacy. Trials of AMS interventions demonstrate ef-
ficacy in reducing rates of both infection and colonization with
antimicrobial-resistant (AMR) bacteria.1,2 Importantly, the associ-
ated reduction in inpatient antimicrobial usage has not been asso-
ciatedwith an increase inmortality.
In comparison with other b-lactams, resistance to carbape-
nems is less prevalent; thus their broad spectrum of antimicrobial
activity remains relatively preserved. However, the prevalence of
carbapenem resistance throughout the world is increasing and
usage of carbapenems should be restricted, unless absolutely ne-
cessary, to maintain their efficacy.3–7 Recognizing this, carbape-
nems are considered ‘critically important’ antimicrobials by the
WHO. Carbapenem sparing, when clinically and microbiologically
appropriate, is therefore a key goal of AMS programmes.
Meropenem is a restricted antimicrobial at our institution and
should be reserved for life-threatening infections or AMR bacteria
(e.g. ESBL-producing Gram-negative organisms). Meropenem
usage should therefore exemplify best practice in infection man-
agement and lessons learned from critically evaluating real-life
meropenemusagewill be applicable to AMSmore generally.
The Scottish Antimicrobial Prescribing Group (SAPG) recently
published an evaluation of their guidance related to carbapenem
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usage, identifying good compliance with local prescribing policies,
lack of confidence in de-escalating therapy and decreased usage
during the 2012–16 study period.8 The aim of this study was to
retrospectively evaluate cases ofmeropenemusage at our institu-
tion in depth to identify targets for AMS interventions. These data
should complement the positive results from national quality im-
provement programmes (QIPs) such as the SAPG guidance by
refining knowledge of the specific elements of clinical practice
amenable to improvement through targetedQIPs.
Methods
Data collection
Meropenem is designated an ‘alert antimicrobial’ at our institution, mean-
ing that it can be used after approval has been granted by an infection spe-
cialist (Medical Microbiologist or Infectious Diseases physician) or for limited
pre-approved empirical indications (Table S1, available as Supplementary
data at JAC-AMR Online) without the requirement for prior discussion with
an infection specialist. An alert form should be completed for any merope-
nemprescription and this form is required for the hospital pharmacy to pro-
vide a supply of meropenem for any patient. Doripenem and imipenem are
not routinely available and ertapenem is reserved for use in the Outpatient
Parenteral Antimicrobial Therapy service. Alert forms received between July
and October 2017were retrospectively reviewed to identify patients receiv-
ing meropenem at our institution (two tertiary care hospitals in Edinburgh,
UK, with a combined total of 1405 beds), which provides regional neurosur-
gery, oncology, haematology, cardiothoracic surgery, transplant (liver, kid-
ney, pancreas and islet cell) and infectious diseases services. Diagnostic
microbiology services are provided to both hospitals by the same labora-
tory. Clinical and microbiological data were gathered from the forms, elec-
tronic patient records and the microbiology laboratory information
management system. Statistical analysis was performed using GraphPad
Prism8 forMacOS, version 8.0.1.
Assessing meropenem necessity
In a subset of cases where meropenem therapy was not rationalized and
positive microbiology results were available, the necessity of continued
meropenem usage was assessed retrospectively by two infection consul-
tants. This assessment was based on the recorded reason for usage, infec-
tion diagnosis, sample type from which the organism was grown,
antibiograms of organisms, antimicrobials already received for the infec-
tion, allergies and the outcome of any bedside reviews by infection special-
ists. Assessments were conducted independently with discussion with a
third reviewer in cases of disagreement. On the basis of the recently
reported MERINO trial, meropenemwas considered preferable to piperacil-
lin/tazobactam for treatment of infection with an ESBL-producing Gram-
negative organism.9
Statistics
Normal data distribution was tested for using the Shapiro–Wilk test. The
Mann–Whitney test was used to compare groups not normally distributed
and the t-test was used to compare normally distributed groups.
Categorical variables were analysed using Fisher’s exact test. Statistical
analyseswere performed using GraphPad Prismversion 7.0.
Ethics
This project was conducted as part of ongoing AMS quality improvement,
utilizing routinely collected data in accordancewith the Caldicott principles,
so further ethics approvalwas not required.
Results
Patient and infection characteristics
Alert forms for meropenemwere received for 107 adult inpatients
during the study period. Themedian patient agewas 63 years (IQR
49.5–71.5) and 48% were female. Eighty-two percent of patients
survived to hospital discharge. Most infections were hospital
acquired (non-ICU setting 23%, ICU acquired 8%) or healthcare
associated (37%, defined per Friedman et al.10), though 32%were
community acquired.Meropenemwas usedmost often by respira-
tory (25%), haematology/oncology (18%), critical care (12%) and
neurosurgery (11%) services. Themost common clinical diagnoses
(Table 1) were respiratory tract infection (37%), urinary tract infec-
tion (13%), intra-abdominal infection (11%), neutropenic sepsis
(8%) and post-neurosurgical CNS infection (6%).
Meropenem usage, prior antimicrobials and
microbiological sampling
Meropenem was used as escalation therapy in 53% of cases and
first-line in 47%. In cases of first-line usage this was empirical in
86% and in response to a microbiology result from a previous epi-
sode in 14%. Escalation of therapy tomeropenemoccurred after a
median of 4 days (IQR 2–7) and use of a median of two prior anti-
microbial agents (IQR 2–3). The most commonly used antimicro-
bials prior to escalation to meropenem were gentamicin (n"32),
amoxicillin (n"20), metronidazole (n"17), piperacillin/tazobac-
tam (n"16), vancomycin (n"13) and ceftriaxone (n"8).
Amongst all patients, the median duration of meropenem usage
was 7 days (IQR 5–14; Figure 1). When used as escalation therapy
the median duration was also 7 days (IQR 4–10) compared with
9.5 (IQR 7–14) when used first-line (P"0.01). Microbiological sam-
plingwas performed in 94% of patients overall, with blood cultures
obtained in 71%. Appropriate sampling was performed least fre-
quently in patients with respiratory tract infections (Figure S1),
whichwere themost common reason formeropenemusage.
Requirement for source control after escalation to
meropenem
An intervention to achieve source control was required in 16/57
(28%) cases after escalation to meropenem. These patients had
received a median of three prior antimicrobials (compared with
two for patients escalated who did not require source control,
P"0.03). The foci of infection and interventions requiredwere usu-
ally predictable reasons for prior antimicrobials to have failed: ser-
ious intra-abdominal infections requiring surgery (n"4), concern
for line infection leading to line removal (n"5), drainage of ascites
or a collection (n"5) or removal of infected prosthetic material
(n"2).
Infection specialist input
Meropenem was used on the basis of a pre-approved empirical
reason in 51% of cases (Table S1), in 29% with no telephone or
bedside input from an infection specialist (Figure 2). The nextmost
common scenario was meropenem initiation on the basis of tele-
phone advice from an infection specialist (43%). In 6.5% of cases
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meropenem was prescribed following a bedside review by an in-
fection specialist (including Infectious Diseases Unit inpatients).
In total, 21 patients had bedside infection specialist review
(20%), including 4 who were managed in the Infectious Diseases
Unit. Of the 17 patients reviewed at the bedside outside the
Infectious Diseases Unit, meropenem was initiated on the basis of
the visit in three cases (day 0) and in the remaining 14 the median
time to review was 3 days (IQR 1–5). The outcome of the review
was to stop (2/14) or switch meropenem to another antimicrobial
(4/14) on the first review or switch on a subsequent review (2/14).
Cumulatively in 8/14 cases the recommendation was not to con-
tinuemeropenem(this advicewas always followed by the patient’s
primary team). In the remaining six cases, therapyhadbeen ration-
alized prior to review in one, the patient was being palliated in one
and continuingmeropenemwas recommended in four.
Overall, infection specialist input (telephone or bedside) was
associated with a significantly shorter duration of meropenem
therapy (median 7 versus 14 days, P,0.0001, Figure 1). In cases
where the outcome of a bedside review was to recommend stop-
ping/switching meropenem the median duration of meropenem
was 4 days (IQR 3–5) comparedwith 7 days in the entire cohort.
Risk factors for MDR organisms in patients receiving
meropenem
One ormore risk factors for carriage of anMDR organismwere pre-
sent in the majority (78%) of patients (Table S2).11–15 Inadequate
datawere available to reliably comment on preceding internation-
al travel, therefore this was not included. At least 55% had
received antimicrobials in the preceding year (including 14%
receiving piperacillin/tazobactam), though this figure will be an
underestimate as primary care prescription records were not
reviewed. An ESBL-producing organism had been isolated from
25%of patients in the past.
Microbiology results and rationalization of therapy
A positive microbiology result was obtained in 65% of patients
(69/107), with growth from a sterile site (blood, CSF, intra-
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Figure 1. Duration of meropenem therapy expressed as median and
IQR. Duration in indicated groups was compared using the Mann–
Whitney test.
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Figure 2. Infection specialist input leading to initiating meropenem ther-
apy. The ‘infection specialist advice’ group denotes instances where
meropenem was recommended by an infection specialist for an indica-
tion not included in the list of pre-approved empirical indications (Table
S1).
Table 1. Clinical diagnoses of patients receiving meropenem
Diagnosis N (%)a
Respiratory tract infection 41 (37.3)
bronchiectasis exacerbation 19 (17.3)
ventilator-associated pneumonia 9 (8.2)
hospital-acquired pneumonia 5 (4.5)
community-acquired pneumonia 4 (3.6)
cystic fibrosis exacerbation 4 (3.6)
Urinary tract infection 14 (12.7)
Intra-abdominal infection 12 (10.9)
Neutropenic sepsis 9 (8.2)
Post-neurosurgical CNS infection 6 (5.5)
Non-infectious diagnosisb 6 (5.5)
Other infectionc 8 (7.3)
CNS infection 4 (3.6)
Surgical site infection 4 (3.6)
Bacteraemia, unknown source 2 (1.8)
Osteomyelitis 2 (1.8)
Skin and soft tissue infection 2 (1.8)
an"110 diagnoses as some patients had .1 diagnosis.
bMethotrexate pneumonitis (n"1); ischaemic bowel (n"1); fever due to
cancer (n"3); and unknown but infection not proven (n"1).
cLine infection (n"5); sepsis from unknown source (n"1); infected spinal
metalwork (n"1); empyema and sub-phrenic collections (n"1).
Meropenem-sparing AMS interventions JAR
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operative sample or aspirate of intra-abdominal, articular or pleu-
ral fluid) in 38 cases and a non-sterile site (sputum, bronchoalveo-
lar lavage, tracheal aspirate, swab, urine) in 31 cases (Table S3).
Meropenem was rationalized in a total of 26 cases (24%; after a
median of 4 days, IQR 2–5) and continued in 74 cases. The patient
died during therapy in six cases and inadequate data were avail-
able for one case. A positivemicrobiology result was strongly asso-
ciated with rationalization of therapy (OR 12.3, 95% CI 2.7–55.5,
P"0.001; Figure 3a). Twenty-four of 26 instances of meropenem
rationalization occurred in response to positive microbiology. A
positive result from a sterile site (17/38) led tomore rationalization
than a result fromanon-sterile site (7/31, P"0.08; Figure 3b).
When meropenem susceptibility was not released on the
microbiology report available to clinicians, rationalization to a
carbapenem-sparing agent was more likely (OR 5.2, 95% CI 1.3–
20.2, P"0.02).
Necessity of continued meropenem usage
Amongst the 74 cases where therapy was continued, positive
microbiology results were available for 40 cases and amongst
these continued meropenem use was retrospectively considered
necessary in a total of 8 cases (20%; Table 2). In the remaining
cases a narrower-spectrum alternative was considered microbio-
logically and clinically appropriate. Infection was due to an ESBL-
producing Gram-negative bacterium in seven cases (bacteraemia
n"3, sputum n"1, urine n"3) but in four cases carbapenem-
sparing agents (not piperacillin/tazobactam) were appropriate
alternatives; therefore continuedmeropenem usage was not con-
sidered necessary. First-line meropenem usage was considered
necessary in 1/19 cases for treatment of Pseudomonas aeruginosa
pneumonia in a patient with a history of ESBL-producing organism
isolation. Continued use was considered necessary in 0/17 cases
where first-linemeropenemwas empirical, with nopriormicrobiol-
ogy suggesting it would be required. Of the patients escalated to
meropenem (21/40), source control was required in 1/7 cases
where continued use was considered necessary and 6/14 where it
was considered unnecessary. Considering the 32/40 cases where
continued meropenem usage was not considered necessary,
355 days of meropenem therapy could theoretically have been
avoided, quantified as 1065 DDD.
Alternative antimicrobials for pathogen-directed
therapy
In caseswith positivemicrobiologywheremeropenemwas contin-
ued and not rationalized, Figure 4 shows the alternative antimicro-
bials that Gram-negative isolates were susceptible to. The b-
lactams temocillin and aztreonam and non-b-lactam alternatives
such as co-trimoxazole, gentamicin and ciprofloxacin were fre-
quently active against bacteria identified.
Discussion
The efficacy of AMS interventions and implementation is increas-
ingly studied, with a recent Cochrane Library review published in
2017,2 and identifying specific elements of clinical practice to tar-
get with such interventions is valuable. This retrospective, in-depth
evaluation of real-life meropenem usage has identified several
tractable targets for carbapenem-sparing AMS interventions that
could be incorporated into national AMS guidance, such as the re-
cently evaluated SAPG QIP.8 These targets are likely to be relevant
to antimicrobials other than carbapenems since carbapenem util-
ization should exemplify best practice in antimicrobial prescribing
and infectionmanagement.
This study is limited by its retrospective nature and reliance on
all relevant decision-making information being recorded in the
electronic patient record. The parameters used to assess merope-
nem necessity represent an over-simplification of clinical decision
making and therefore could underestimate the number of cases
where meropenem usage was necessary for reasons other than
those reviewed, but the decision to restrict this analysis to cases
with positivemicrobiology results should ameliorate this limitation.
The time period included in this review overlaps with a shortage of
piperacillin/tazobactam, which may also have influenced some
antimicrobial decisions, although in cases with positive microbiol-
ogy available there were no organisms where the only rationaliza-
tion option was piperacillin/tazobactam. Another limitation is an
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Figure 3. Influence of microbiology results on meropenem rationalization. Proportions were compared using Fisher’s exact test. (a) Positive and
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inability to identify and review potential cases where meropenem
was used but no alert form was completed (though in such cases
continued usage of meropenem should not be possible as an alert
form is required for the pharmacy to release the drug).
Based on our data we have identified the following seven areas
of practice as targets for carbapenem-sparing AMS interventions.
1. Microbiological sampling
The basic stepofmicrobiological sampling, particularly prior to anti-
microbial administration, is unsurprisingly critical to generate data
to allow therapy to be rationalized and was strongly associated
with rationalization of meropenem. Whilst the site of infection dic-
tates which specific samples may be obtained, blood cultures are
always possible butwere not performed in 29% of cases.
2. Source control
Source control was required in 28% of cases after escalating ther-
apy to meropenem (after receiving more prior antimicrobials than
patients not requiring source control), and was usually a predict-
able contributor to antimicrobial failure (e.g. collections and
infected prostheses). When antimicrobials are failing despite sev-
eral rounds of escalation the necessity of source control should be
considered at an earlier stage, before escalating tomeropenem.
3. Infection specialist input
Infection specialist input, by bedside review or telephone consult-
ation, was associated with a reduced duration of meropenem
therapy. Overall, 20% of patients receivingmeropenemwere seen
at the bedside by an infection specialist. Considering such cases
(outside the Infectious Diseases Unit), the recommendation was
to stop/switchmeropenem in 8/17 cases. Thiswas associatedwith
a reduction in meropenem duration to a median of 4 days (versus
7 days for the whole cohort). In 9/17 cases the review happened
.1 day after startingmeropenem.We suggest that increased cap-
acity for early, potentially unsolicited, bedside review of patients
receiving meropenem has the potential to reduce duration of
usage. Bedside review by an infection specialist is already known
to improve AMS16 and also clinical outcomes in bacteraemia
(including specifically Staphylococcus aureus bacteraemia), AMR
bacterial infection and candidaemia.17–20
4. Approve limited duration of meropenem
Microbiological diagnosis of organisms susceptible to antimicro-
bials other thanmeropenem (Figure 4) often did not lead to ration-
alization of therapy. In cases where meropenem was rationalized
this was done after a median of 4 days. Supply of a limited dur-
ation of meropenem (e.g. through provision of a permission code
for a defined number of days) with the requirement for re-
discussion with an infection specialist on day 4 could increase the
proportion of caseswhere therapy is rationalized, rather than com-
pleting a 7 day course by default. A retrospective before-and-after
study, comparing initial authorization of restricted antimicrobials
with the additional requirement for re-authorization on day 3,
reported reduced duration of usage of restricted antimicrobials
and nodifference in hospitalmortality.21
5. Do not report meropenem susceptibility, where
appropriate, when releasing microbiology results
In caseswith positivemicrobiology, not reportingmeropenemsus-
ceptibility was associated with increased likelihood of therapy
Table 2. Retrospective assessment of necessity of continued meropenem usage in cases with positive microbiology where therapy was not
rationalized
Reason for meropenem usage
Positive
microbiology
Meropenem
rationalized
Meropenem
continued
Continued meropenem
usage necessarya
All patients 64 24 40 8/40
First-line therapy
empirical 25 8 17 0/17
previous microbiology 5 3 2 1/2
Escalation therapy 34 13 21 7/21
Values are shown as numbers of patients.
aRetrospectively assessed by two infection consultants based on the recorded reason for usage, infection diagnosis, sample type from which organ-
ism was grown, antibiograms of organisms, antimicrobials already received for the infection, allergies and the outcome of any bedside reviews by in-
fection specialists.
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Figure 4. Rationalization options for pathogen-directed treatment of
Gram-negative bacteria. Susceptibility tests for all listed antimicrobials
were not performed for all isolates; therefore there is no consistent de-
nominator for each antimicrobial. Results are shown for 35 bacterial iso-
lates recovered from infections where meropenem therapy was
continued and not rationalized following positive microbiology.
Meropenem-sparing AMS interventions JAR
5 of 7
D
ow
nloaded from
 https://academ
ic.oup.com
/jacam
r/article-abstract/1/2/dlz042/5568234 by U
niversity of Edinburgh user on 12 Septem
ber 2019
being rationalized to a carbapenem-sparing agent. Therefore, the
necessity of reporting meropenem susceptibility when releasing
microbiology results should be carefully considered and avoided if
the organism is susceptible to appropriate alternatives.
6. First-line meropenem usage
First-linemeropenemusewas common (47%), associated with an
increased duration of therapy, and continuation was usually un-
necessary in our retrospective assessment of cases with positive
microbiology (18/19 unnecessary). In the one case where it was
considered necessary, this was predicted by previous isolation of
an ESBL-producing organism from the patient. Therefore, use of
meropenem as a first-line antimicrobial in the absence of previous
specific microbiology (prior ESBL organism isolation) is not sup-
ported by the results of this study and should be avoided.
Carbapenems should bemaintained as reserve antimicrobials (not
in routine empirical recommendations/guidelines) with regular re-
viewof local resistance patterns and clinical use.
7. Increase familiarity with carbapenem-sparing
antimicrobials
Apparent reluctance to use these alternatives to rationalize mero-
penem therapy could relate to non-infection specialist clinicians
being unfamiliar with less commonly used antimicrobials
(Figure 4). A recent meta-analysis identified a similar association
between carbapenem usage and Clostridioides (Clostridium) diffi-
cile infection (CDI, OR 1.84) and quinolone usage (OR 1.66), provid-
ing some justification for quinolone usage as a carbapenem-
sparing strategywithout excess risk of CDI.22 Following publication
of the MERINO trial it is important to note that in four out of seven
cases where meropenem was continued for an ESBL-producing
Gram-negative organism this was not necessary as other agents
(not piperacillin/tazobactam) would have been suitable
alternatives.
By using carbapenem usage as a probe, we highlight that in
real-life clinical practice core aspects of infection management
represent simple, tractable targets for AMS interventions
(Figure 5). The importance of these elements of practice should be
continually emphasized to all clinicians and warrant inclusion in
national QIPs. To derive the maximum benefit from molecular
diagnostic technologies, and eventually novel therapeutics, it is
critical to ensure ‘the basics’ ofmanaging infection are consistently
donewell as a core element of AMS.
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• Ensure appropriate microbiological samples are obtained, including blood cultures. 
• Pursue source control prior to escalation to meropenem if an obvious focus is present (e.g. prosthetic 
material, line, collection). 
• Seek input from an infection specialist when using meropenem, even for a pre-approved indication. 
• Increase capacity for early unsolicited bedside reviews by infection specialists for patients receiving 
restricted antimicrobials such as meropenem. 
• Approve limited durations of meropenem therapy to ensure rationalization is actively considered by day 
3-4 of therapy. 
• Do not report meropenem susceptibility of an organism when releasing microbiology results unless there 
are no appropriate alternatives. 
• Limit first-line meropenem usage outwith cases of prior ESBL organism isolation. 
• Increase clinician’s familiarity with less frequently used alternative antimicrobials for treatment of 
Gram-negative infections (Figure 4). 
Figure 5. Tractable targets for meropenem-sparing AMS interventions.
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